Elanco Animal Health Incorporat

Valuation Analysis

About the Company

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well

Elanco Animal Health Incorporat Stock at a Glance

Elanco Animal Health Incorporat (ELAN) is currently trading at $24.17 with a market capitalization of $12.1B. The 52-week range spans from $13.16 to $27.72; the current price is 12.8% below the yearly high. Year-over-year revenue growth stands at +14.9%.

💰 Dividend

Elanco Animal Health Incorporat currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

14 analysts rate Elanco Animal Health Incorporat (ELAN) on consensus: Strong Buy. The average price target is $29.79, implying +23.23% from the current price. Analyst price targets range from $23.00 to $32.00.

Elanco Animal Health Incorporat: The Investment Case in Detail

Elanco Animal Health Incorporat (ELAN) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 14.9% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Wall Street consensus sits at Strong Buy with an average price target implying roughly 23.23% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 10.55% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

At a PEG of 4.04, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

What to Watch Next

• The analyst consensus price target implies 23.23% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to above-average price swings, elevated short interest (10.55%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Elanco Animal Health Incorporat?

Compare top-rated brokers — low fees, trusted providers, fully regulated.